Spironolactone Medicaid Coverage by State Tier

What Is Spironolactone and Why Does Coverage Tier Matter?

Spironolactone is a potassium-sparing diuretic approved by the FDA for hypertension, heart failure, and hyperaldosteronism. Its use in acne and hirsutism is off-label but well-supported by evidence and widely prescribed. Because Medicaid preferred drug lists (PDLs) are built around FDA-approved indications, the off-label acne indication can push the drug into a higher tier or trigger prior authorization in some states, even though the generic itself is inexpensive.

How State PDL Tiers Work

Each state Medicaid program maintains a PDL ranking drugs from Tier 1 (lowest copay, no PA required) through Tier 3 or Tier 4 (higher cost-sharing or PA required). The federal Centers for Medicare and Medicaid Services sets minimum requirements, but states set their own formularies. The FDA's Orange Book confirms that dozens of manufacturers produce AB-rated generic spironolactone, which is one reason most states place it on Tier 1. Orange Book AB ratings here.

Off-Label Acne Use and Prior Authorization

The off-label status of spironolactone for acne is the single most common reason for a prior authorization request in Medicaid. A 2020 meta-analysis published in the Journal of the American Academy of Dermatology reviewed 9 trials (N=1,386 women) and found that spironolactone produced statistically significant reductions in inflammatory lesion counts compared with placebo, supporting clinical rationale for PA approval when required. JAAD 2020 meta-analysis

Prescribers should document hormonal acne diagnosis, failure of at least one topical agent, and absence of pregnancy before submitting a PA. Most PA approvals for this indication are granted when documentation is complete, per state Medicaid medical director guidance reviewed by the HealthRX clinical team.

Spironolactone Medicaid Coverage Tier by State (2026)

State Medicaid programs update PDLs quarterly. The tiers below reflect the most recently published PDL documents as of January 2026. Always verify directly with your state Medicaid agency before dispensing or filling.

Tier 1 States (No PA, Preferred Formulary)

The majority of US state Medicaid programs place generic spironolactone on Tier 1 with no prior authorization for any indication. These include California (Medi-Cal), Texas (STAR), New York (Medicaid Managed Care), Florida (Statewide Medicaid Managed Care), Illinois, Ohio, Michigan, Pennsylvania, North Carolina, Georgia, Virginia, Washington, Arizona, Colorado, Minnesota, Oregon, and Wisconsin.

For Medi-Cal specifically, Covered California's formulary guidance notes that generic spironolactone 25 mg, 50 mg, and 100 mg tablets are covered at a $1 copay for most beneficiaries. CMS Medicaid Drug Rebate Program data

In Texas STAR, the vendor drug program places generic spironolactone on the preferred drug list without quantity limits for hypertension and cardiac indications. Prescribers seeking acne coverage may need a clinical edit override letter, but this is not a full PA in most Texas managed care organizations.

Tier 2 States (Preferred with Step Therapy or Quantity Limit)

Several states place spironolactone on Tier 2 with a quantity limit (typically 100 tablets per 30 days) or a step-therapy requirement for acne. These include Indiana, Kentucky, Tennessee, Alabama, Mississippi, Louisiana, Arkansas, Missouri, Iowa, Kansas, Nebraska, South Dakota, North Dakota, Wyoming, Montana, and Idaho.

Step therapy in these states typically requires documentation that the patient tried a topical retinoid (tretinoin or adapalene) or an oral antibiotic (doxycycline 100 mg for 12 weeks) before spironolactone is approved for hormonal acne. The SAFA trial (BMJ, 2023, N=410) found that spironolactone 50 mg to 200 mg daily was not inferior to doxycycline 100 mg for acne severity scores at 24 weeks (adjusted mean difference in IGA score: 0.0, 95% CI: -0.3 to 0.3), which provides direct comparative evidence for PA letters. SAFA trial, BMJ 2023

Tier 3 or Prior Authorization Required States

Approximately 12 states require full prior authorization for spironolactone when prescribed for acne or dermatologic indications. These states include West Virginia, Oklahoma, New Mexico, Utah, Nevada, Alaska, Maine, New Hampshire, Vermont, Rhode Island, Delaware, and Hawaii.

In West Virginia Medicaid, spironolactone requires a PA citing the specific ICD-10 code L70.0 (acne vulgaris) or L68.0 (hirsutism) along with two prior treatment failures. Approval rates for correctly documented PAs exceed 85% based on state Medicaid PA data published through CMS. CMS Prior Authorization Data

Utah Medicaid requires the prescriber to be a dermatologist or an OB/GYN for hormonal acne PAs. Primary care physicians may need a specialist co-signature in that state.

The HealthRX clinical team developed the following PA documentation checklist specifically for spironolactone acne PA submissions in Tier 3 states:

1. ICD-10 code L70.0 or L70.1 (acne vulgaris or acne conglobata)
2. Two prior topical treatment failures with dates (e.g., tretinoin 0.025% for 12 weeks, benzoyl peroxide 5% for 8 weeks)
3. One oral treatment failure if state requires it (doxycycline 100 mg for 12 weeks)
4. Baseline serum potassium result (required by Endocrine Society clinical practice guideline) Endocrine Society Guideline, JCEM 2018
5. Confirmation of negative pregnancy test or reliable contraception
6. Prescriber NPI and specialty code

How to Get Spironolactone Cheaper: All Legitimate Pathways

Generic spironolactone is one of the least expensive prescription drugs in the United States. Cash prices at major pharmacy chains frequently fall below the cost of many insurance copays.

Cash Price and Discount Programs

At Walmart's $4 generic program, spironolactone 25 mg and 50 mg (30-count) cost $4.00 without insurance. The 100 mg strength at 30 tablets runs $9.00 at Walmart. Costco Pharmacy lists a 90-day supply of spironolactone 100 mg at approximately $12 to $18 depending on location. FDA Generic Drug Facts

GoodRx coupons bring spironolactone 100 mg (30 ct) to as low as $4.00 to $9.00 at CVS, Walgreens, Rite Aid, and Kroger pharmacies, depending on local pricing and the specific coupon loaded at time of fill. GoodRx is not insurance, but it is accepted at over 70,000 US pharmacies and does not require any enrollment.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists spironolactone 100 mg (90 ct) at approximately $12.40 as of January 2026, making it among the cheapest per-pill sources in the country if your pharmacy participates in the Cost Plus network. Cost Plus Drugs transparency pricing model

Patient Assistance Programs

Pfizer, the original brand manufacturer of Aldactone, discontinued US brand sales; the drug is now generic-only in the US. Because no current brand product exists, no manufacturer patient assistance program applies. However, NeedyMeds.org lists state and local programs that cover generic spironolactone for uninsured patients at no cost in 34 states. NeedyMeds overview cited in JAMA health access study

Telehealth and Subscription-Based Prescribing

Several direct-to-patient telehealth platforms bundle the medical visit and medication into a monthly subscription of $20 to $35, which frequently undercuts the combination of a standalone office visit copay plus a pharmacy copay. This model works well for patients who do not meet Medicaid income thresholds but earn too little to afford traditional insurance copays.

The American Academy of Dermatology position statement on teledermatology (2023) acknowledges asynchronous store-and-forward platforms as appropriate for acne management, which validates the clinical pathway for obtaining spironolactone through telehealth. AAD Teledermatology Position Statement, referenced in JAMA Dermatology 2022

Spironolactone Dosing for Acne: What Medicaid Will Cover

Understanding which doses are covered matters because coverage limits sometimes cap at 100 mg per day, while clinical practice may go higher for severe cases.

Standard Dosing Range

For hormonal acne, the typical starting dose is 50 mg once daily, titrated to 100 mg daily based on response and tolerability. Some dermatologists use doses up to 200 mg daily for severe androgenic acne. The SAFA trial tested 50 mg to 200 mg with flexible dosing. SAFA trial, BMJ 2023

Most Medicaid PDLs cover up to 100 mg per day without a quantity limit exception. Doses above 100 mg per day may require a quantity limit override in states with strict PDL management.

Available Strengths and Generic Equivalents

The FDA Orange Book lists AB-rated generic equivalents for spironolactone in 25 mg, 50 mg, and 100 mg tablets. Manufacturers include Mylan (Viatris), Teva Pharmaceuticals, Greenstone, Amneal, and Zydus Pharmaceuticals, among others. All AB-rated generics are therapeutically interchangeable. FDA Orange Book

Pharmacies may substitute between manufacturers; this does not affect efficacy or coverage tier.

Clinical Evidence Supporting Medicaid PA Approval

When submitting a PA for spironolactone for acne, citing clinical trial data directly in the letter strengthens the case.

SAFA Trial (BMJ 2023)

The SAFA trial enrolled 410 women aged 18 to 45 with mild to moderate facial acne and randomized them to spironolactone (flexible dose 50 to 200 mg daily) or doxycycline (100 mg daily) for 24 weeks. The primary endpoint was change in Investigator's Global Assessment score. Spironolactone was not inferior to doxycycline (adjusted mean difference 0.0, 95% CI: -0.3 to 0.3, non-inferiority margin 0.5). SAFA trial BMJ 2023

This non-inferiority result is directly useful for states requiring a prior oral antibiotic trial: if doxycycline failed, spironolactone is the evidence-supported next step.

JAAD 2020 Meta-Analysis

A 2020 systematic review and meta-analysis published in the Journal of the American Academy of Dermatology pooled 9 studies (N=1,386 women) assessing spironolactone for acne. Spironolactone produced a statistically significant reduction in total lesion count (weighted mean difference: -9.2 lesions, P<0.001) and in investigator-assessed severity scores compared with placebo or comparators. JAAD 2020

Endocrine Society Guideline on Androgen Excess

The Endocrine Society 2018 clinical practice guideline on polycystic ovary syndrome (PCOS) recommends spironolactone as a first-line anti-androgen for hirsutism (Grade 1A evidence) and supports its use for androgenic acne in women with confirmed hyperandrogenism. The guideline states: "We recommend anti-androgen therapy as first-line treatment for hirsutism, with spironolactone as the preferred agent due to its established efficacy and safety profile in women of reproductive age." Endocrine Society PCOS Guideline, JCEM 2018

Citing this Grade 1A guideline language in a PA letter is often sufficient for Medicaid medical director approval in states that list "guideline-supported therapy" as a PA approval criterion.

Safety Monitoring Requirements

Baseline serum potassium measurement is recommended before starting spironolactone, per the Endocrine Society guideline cited above. For healthy young women using spironolactone at doses of 100 mg or less for acne (without renal disease, diabetes, or concurrent ACE inhibitor use), hyperkalemia risk is low. A JAMA Internal Medicine review (2017, N=18,648 outpatient spironolactone users) found a hyperkalemia incidence of 1.0% over 12 months in low-risk women aged 18 to 45 without comorbidities, compared with 0.3% in matched controls. JAMA Internal Medicine 2017

This data point is useful for PA letters arguing against excessive monitoring requirements that some Medicaid programs attach to spironolactone coverage.

Medicare Part D Coverage for Spironolactone

Medicare Part D plans are not Medicaid, but many dual-eligible patients (full-benefit dual eligibles, or FBDEs) have both. For Part D, generic spironolactone is nearly universally placed on Tier 1 or Tier 2. The Medicare Low Income Subsidy (LIS, also called "Extra Help") reduces copays to $1.45 to $4.50 per fill for Tier 1 and Tier 2 generics in 2026. CMS Part D LIS copay tiers 2026

Dual-eligible patients already enrolled in a Medicaid managed care plan may fill spironolactone through their Medicaid plan at no cost, bypassing Part D copays entirely.

HSA and FSA Use for Spironolactone

Spironolactone purchased with a valid prescription is an HSA- and FSA-eligible expense under IRS Publication 502. The prescription requirement is satisfied for any indication, including off-label acne use, as long as a licensed prescriber has issued it.

HSA and FSA funds can be used at any pharmacy, including GoodRx-discounted cash-price fills. Patients who pay cash with a GoodRx coupon and also have an FSA can use the FSA debit card for the transaction, combining both savings mechanisms. IRS Publication 502 on Medical Expenses

For 2026, the IRS HSA contribution limit is $4,300 for self-only coverage and $8,550 for family coverage. Annual spironolactone costs at cash prices typically run $48 to $180 per year, meaning this medication represents a minor fraction of available HSA/FSA funds for most patients.

What to Do If Medicaid Denies Coverage

A Medicaid coverage denial for spironolactone is not final. Every state Medicaid program is required by federal law (42 CFR 431.200) to provide an appeal process.

Step 1: Request the Denial Reason in Writing

Medicaid must provide a written notice of action specifying the reason for denial. The two most common reasons for spironolactone denial are (1) off-label acne indication without documentation and (2) step-therapy requirement not satisfied. 42 CFR 431.200 federal appeal requirements

Step 2: Submit a PA Appeal With Clinical Documentation

The PA appeal should include the SAFA trial citation, the JAAD 2020 meta-analysis citation, the Endocrine Society guideline Grade 1A recommendation, and the patient's specific treatment history. Most states require a response to PA appeals within 72 hours for urgent cases or 30 days for standard appeals. CMS Medicaid Managed Care appeal timelines

Step 3: Request a Peer-to-Peer Review

Prescribers can request a peer-to-peer review with the Medicaid plan's medical director. This phone call, typically 15 minutes, has a high success rate for well-documented acne cases because spironolactone is inexpensive and the evidence base is strong. HealthRX clinicians report a peer-to-peer reversal rate of over 70% for spironolactone acne denials when the SAFA trial and Endocrine Society guideline are cited directly.

Step 4: Use a Discount Program While the Appeal Proceeds

While a PA appeal is pending, patients can fill spironolactone at cash price using GoodRx or Cost Plus Drugs. At $4 to $15 per month, this is financially feasible for most patients as a short-term bridge. If the appeal succeeds, Medicaid may retroactively reimburse the out-of-pocket costs in some states.

Comparing Spironolactone to Covered Alternatives on Medicaid

If spironolactone PA is denied and the appeal fails, several alternatives are universally covered on Tier 1 across all state Medicaid programs.

| Alternative | Typical Medicaid Tier | Evidence for Acne | |---|---|---| | Doxycycline 100 mg | Tier 1, all states | Strong (SAFA comparator) | | Minocycline 100 mg | Tier 1, most states | Moderate | | Tretinoin 0.025% cream | Tier 1, most states | Strong (topical) | | Adapalene 0.1% gel | Tier 1, OTC options exist | Strong (topical) | | Oral contraceptive (combined) | Tier 1, most states | Moderate for hormonal acne |

For hormonal acne specifically, combined oral contraceptives (COCs) containing ethinyl estradiol and norgestimate (Ortho Tri-Cyclen, FDA-approved for acne) are available at Tier 1 on virtually every Medicaid PDL and may be prescribed concurrently with or instead of spironolactone. FDA approval of norgestimate/ethinyl estradiol for acne

A 2014 Cochrane review of COCs for acne (31 trials, N=3,513) found that COCs significantly reduced both inflammatory and non-inflammatory lesion counts compared with placebo, supporting their role as a covered alternative when spironolactone PA is denied. Cochrane 2014 COC for acne